Submit complete Phase-I CT report: CDSCO Panel Tells Biological E on Bivalent Typhoid and Paratyphoid A Conjugate Vaccine
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-23 12:30 GMT | Update On 2024-07-23 12:30 GMT
Advertisement
New Delhi: Reviewing the interim Phase-I clinical trial report of Typhoid and Paratyphoid A Conjugate Vaccine Bivalent, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the vaccine major Biological E to submit a complete Phase-I clinical trial report conducted in Europe for further deliberation of the proposal.
This came after the vaccine major Biological E presented an interim Phase-I clinical trial report conducted in Europe along with the Phase-II Clinical Trial Protocol titled “A prospective multicentre, observer-blind, Phase-II study to evaluate the safety and immunogenicity of Biological E’s Bivalent Typhoid and Paratyphoid A conjugate vaccine when administered to healthy adults, children/adolescents and infants/ toddlers in India”.
Typhoid and paratyphoid (also known as typhoid and paratyphoid fever) are bacterial infections of the intestinal tract and bloodstream. The bacterium responsible for typhoid is called Salmonella typhi and the bacterium responsible for paratyphoid is Salmonella paratyphi.
At the recent SEC meeting for Vaccine held on June 25, 2024, the expert panel reviewed the interim Phase-I clinical trial report conducted in Europe along with the Phase-II Clinical Trial Protocol titled “A prospective multicentre, observer-blind, Phase-II study to evaluate the safety and immunogenicity of Biological E’s Bivalent Typhoid and Paratyphoid A conjugate vaccine when administered to healthy adults, children/ adolescents and infants/toddlers in India”.
After detailed deliberation, the committee recommended submitting a complete Phase-I clinical trial report conducted in Europe for further deliberation of the proposal.
Also Read:Dr Reddy's Laboratories Gets CDSCO Panel Nod To Study Rebamipide, Sodium Alginate Suspension
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.